Document Type
Oral Presentation
Location
Oxford Convention Center, 102 Ed Perry Boulevard Oxford, MS 38655
Event Website
https://oxfordicsb.org/
Start Date
18-4-2024 11:15 AM
End Date
18-4-2024 11:30 AM
Description
Metabolic enzyme and/or transporter-mediated pharmacokinetic (PK) changes in a drug caused by concomitant herbal products have been a primary issue of herb and drug interactions (HDIs), because PK changes of a drug may result in the alternation of efficacy and toxicity. Studies on HDIs have been carried out by predictive in vitro and in vivo preclinical studies, and clinical trials. Nevertheless, the discrepancies between predictive data and the clinical significance on HDIs still exist, and different reports of HDIs add to rather than clarify the confusion regarding the use of herbal products and drug combinations. Here, the underlying mechanisms causing PK-based HDIs mainly focusing on the “reverse pharmacokinetics (e.g., systemic exposure and local tissue distributions)” are summarized. In addition, dose and treatment period effects as challenging issues in study designs and interpretations of HDI evaluation should be also considered. Several examples of HDIs are provided to describe these multifaced factors to be considered in the interpretation of HDIs.
Recommended Citation
Choi, Young Hee, "Multifaced factors to cause conflicting outcomes in drug-herb interactions mainly focusing on reverse pharmacokinetics" (2024). Oxford ICSB. 26.
https://egrove.olemiss.edu/icsb/2024_ICSB/Schedule/26
Publication Date
April 2024
Accessibility Status
Searchable text
Included in
Multifaced factors to cause conflicting outcomes in drug-herb interactions mainly focusing on reverse pharmacokinetics
Oxford Convention Center, 102 Ed Perry Boulevard Oxford, MS 38655
Metabolic enzyme and/or transporter-mediated pharmacokinetic (PK) changes in a drug caused by concomitant herbal products have been a primary issue of herb and drug interactions (HDIs), because PK changes of a drug may result in the alternation of efficacy and toxicity. Studies on HDIs have been carried out by predictive in vitro and in vivo preclinical studies, and clinical trials. Nevertheless, the discrepancies between predictive data and the clinical significance on HDIs still exist, and different reports of HDIs add to rather than clarify the confusion regarding the use of herbal products and drug combinations. Here, the underlying mechanisms causing PK-based HDIs mainly focusing on the “reverse pharmacokinetics (e.g., systemic exposure and local tissue distributions)” are summarized. In addition, dose and treatment period effects as challenging issues in study designs and interpretations of HDI evaluation should be also considered. Several examples of HDIs are provided to describe these multifaced factors to be considered in the interpretation of HDIs.
https://egrove.olemiss.edu/icsb/2024_ICSB/Schedule/26
Comments
This research was supported by the National Research Foundation of the Republic of Korea (NRF) in the Korean government (MSIT) [grant numbers: NRF-2016R1C1B10`0849, NRF-2018R1A5A2023127, NRF-2021R1A2C1094462, and RS-2023-00261934].